← Back to Screener
National Research Corporation Common Stock (Delaware) (NRC)
Price$18.18
Favorite Metrics
Price vs S&P 500 (26W)48.31%
Price vs S&P 500 (4W)-5.39%
Market Capitalization$410.12M
P/E Ratio (Annual)35.35x
Indicated Dividend Yield (Annual)3.55%
All Metrics
P/CF (Annual)15.51x
Book Value / Share (Quarterly)$0.62
P/TBV (Annual)36.15x
Indicated Dividend (Annual)$0.48
Revenue Growth (3Y)-3.23%
Cash Flow / Share (Quarterly)$0.70
Payout Ratio (TTM)70.42%
Price vs S&P 500 (YTD)-8.08%
Gross Margin (TTM)61.88%
Net Profit Margin (TTM)8.44%
EPS (TTM)$0.52
10-Day Avg Trading Volume0.07M
EPS Excl Extra (TTM)$0.52
Revenue Growth (5Y)0.61%
EPS (Annual)$0.52
Dividend / Share (Annual)$0.48
ROI (Annual)12.47%
Gross Margin (Annual)61.88%
Net Profit Margin (5Y Avg)18.58%
Cash / Share (Quarterly)$0.18
P/E Basic Excl Extra (TTM)35.35x
Revenue Growth QoQ (YoY)-4.64%
EPS Growth (5Y)-18.62%
P/E Normalized (Annual)35.35x
ROA (Last FY)8.60%
Revenue Growth TTM (YoY)-3.96%
EBITD / Share (TTM)$1.34
ROE (5Y Avg)62.71%
Operating Margin (TTM)16.44%
Cash Flow / Share (Annual)$0.70
P/B Ratio29.32x
P/B Ratio (Quarterly)30.40x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)3.53x
Net Interest Coverage (TTM)4.84x
ROA (TTM)8.48%
EPS Growth QoQ (YoY)-71.11%
EV / EBITDA (TTM)16.10x
EPS Incl Extra (Annual)$0.52
Current Ratio (Annual)0.55x
Quick Ratio (Quarterly)0.45x
3-Month Avg Trading Volume0.10M
52-Week Price Return71.23%
EV / Free Cash Flow (Annual)30.81x
P/E Incl Extra (TTM)35.35x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.52
P/S Ratio (Annual)2.99x
Asset Turnover (Annual)1.02x
52-Week High$22.79
Operating Margin (5Y Avg)26.53%
EPS Excl Extra (Annual)$0.52
CapEx CAGR (5Y)21.88%
Tangible BV CAGR (5Y)-28.49%
26-Week Price Return57.06%
Quick Ratio (Annual)0.45x
13-Week Price Return-13.48%
Total Debt / Equity (Annual)5.65x
Current Ratio (Quarterly)0.55x
Enterprise Value$485.024
Revenue / Share Growth (5Y)3.41%
Asset Turnover (TTM)1.00x
Book Value / Share Growth (5Y)-24.57%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)12.99%
Cash / Share (Annual)$0.18
3-Month Return Std Dev73.06%
Gross Margin (5Y Avg)62.26%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)-9.93%
EBITDA Interim CAGR (5Y)-12.53%
ROE (Last FY)82.92%
Net Interest Coverage (Annual)4.84x
EPS Basic Excl Extra (Annual)$0.52
P/FCF (TTM)20.62x
Receivables Turnover (TTM)12.22x
EV / Free Cash Flow (TTM)30.81x
Total Debt / Equity (Quarterly)5.65x
EPS Incl Extra (TTM)$0.52
Receivables Turnover (Annual)12.22x
ROI (TTM)12.07%
Dividend Growth Rate (5Y)2.80%
P/S Ratio (TTM)2.99x
Pretax Margin (5Y Avg)24.76%
Revenue / Share (Annual)$6.13
Tangible BV / Share (Annual)$0.52
Free OCF CAGR (5Y)-15.55%
Price vs S&P 500 (52W)36.13%
P/E Ratio (TTM)35.35x
EPS Growth TTM (YoY)-50.67%
Year-to-Date Return-3.94%
5-Day Price Return7.23%
EPS Normalized (Annual)$0.52
ROA (5Y Avg)20.16%
Net Profit Margin (Annual)8.44%
Month-to-Date Return6.18%
Cash Flow / Share (TTM)$1.40
EBITD / Share (Annual)$1.34
EPS Growth (3Y)-25.78%
Operating Margin (Annual)16.44%
LT Debt / Equity (Annual)5.36x
P/CF (TTM)15.51x
ROI (5Y Avg)28.38%
P/E Excl Extra (TTM)35.35x
LT Debt / Equity (Quarterly)5.36x
EPS Basic Excl Extra (TTM)$0.52
P/TBV (Quarterly)36.15x
Payout Ratio (Annual)94.64%
P/B Ratio (Annual)30.40x
Dividend / Share (TTM)$0.48
Pretax Margin (TTM)12.99%
Book Value / Share (Annual)$0.62
Price vs S&P 500 (13W)-16.35%
Net Margin Growth (5Y)-21.31%
Dividend Yield (TTM)2.68%
Beta0.41x
P/FCF (Annual)26.05x
Revenue / Share (TTM)$6.30
ROE (TTM)58.51%
52-Week Low$9.76
Analyst Recommendations
Sep 2021
Oct 2021
Nov 2021
Dec 2021
2.25
2.25
2.25
2.25
Industry Peers — R&D — Physical Sciences(9)
| Symbol | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|
NRCNational Research Corporation Common Stock (Delaware) | 35.35x | 58.51% | 0.61% | 3.55% | $18.18 |
IQVIQVIA Holdings Inc. | 22.06x | 22.28% | 7.50% | — | $176.76 |
INCYIncyte Genomics Inc | 15.00x | 29.15% | 14.03% | — | $96.92 |
MEDPMedpace Holdings, Inc. Common Stock | 32.96x | 118.82% | 22.27% | — | $528.44 |
CRLCharles River Laboratories International, Inc. | — | -4.40% | 6.55% | — | $185.54 |
ABSIAbsci Corporation Common Stock | — | -59.68% | -10.14% | — | $3.95 |
OABIOmniAb, Inc. Common Stock | — | -23.99% | -4.31% | — | $1.55 |
MXCTMaxCyte, Inc. Common Stock | — | -24.06% | 4.76% | — | $0.86 |
NOTVInotiv, Inc. Common Stock | — | -50.77% | 53.35% | — | $0.29 |
ISPCiSpecimen Inc. Common Stock | — | -496.37% | -25.09% | — | $0.13 |
About
National Research Corp provides analytics and insights that help healthcare providers, payers, and other healthcare organizations measure and improve patient and employee experiences while increasing engagement and loyalty. The company operates primarily in the United States and Canada, with the majority of its revenue derived from the U.S. market.